CYCN
Price
$3.21
Change
+$0.24 (+8.11%)
Updated
Jun 3 closing price
Capitalization
9.81M
IBIO
Price
$0.84
Change
+$0.02 (+2.44%)
Updated
Jun 3 closing price
Capitalization
13.91M
Interact to see
Advertisement

CYCN vs IBIO

Header iconCYCN vs IBIO Comparison
Open Charts CYCN vs IBIOBanner chart's image
Cyclerion Therapeutics
Price$3.21
Change+$0.24 (+8.11%)
Volume$48.25K
Capitalization9.81M
iBio
Price$0.84
Change+$0.02 (+2.44%)
Volume$181.02K
Capitalization13.91M
CYCN vs IBIO Comparison Chart
Loading...
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYCN vs. IBIO commentary
Jun 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYCN is a Buy and IBIO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2025
Stock price -- (CYCN: $3.20 vs. IBIO: $0.84)
Brand notoriety: CYCN and IBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYCN: 282% vs. IBIO: 14%
Market capitalization -- CYCN: $9.81M vs. IBIO: $13.91M
CYCN [@Biotechnology] is valued at $9.81M. IBIO’s [@Biotechnology] market capitalization is $13.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $321.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYCN’s FA Score shows that 1 FA rating(s) are green whileIBIO’s FA Score has 1 green FA rating(s).

  • CYCN’s FA Score: 1 green, 4 red.
  • IBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, CYCN is a better buy in the long-term than IBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYCN’s TA Score shows that 5 TA indicator(s) are bullish while IBIO’s TA Score has 5 bullish TA indicator(s).

  • CYCN’s TA Score: 5 bullish, 5 bearish.
  • IBIO’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, IBIO is a better buy in the short-term than CYCN.

Price Growth

CYCN (@Biotechnology) experienced а +9.81% price change this week, while IBIO (@Biotechnology) price change was +4.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.76%. For the same industry, the average monthly price growth was +2.77%, and the average quarterly price growth was +0.74%.

Reported Earning Dates

CYCN is expected to report earnings on Mar 04, 2025.

IBIO is expected to report earnings on May 02, 2025.

Industries' Descriptions

@Biotechnology (+5.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IBIO($13.9M) has a higher market cap than CYCN($9.81M). CYCN YTD gains are higher at: -0.466 vs. IBIO (-65.637). CYCN has higher annual earnings (EBITDA): -3.63M vs. IBIO (-15.11M). IBIO has more cash in the bank: 4.96M vs. CYCN (3.23M). CYCN has less debt than IBIO: CYCN (0) vs IBIO (3.76M). CYCN has higher revenues than IBIO: CYCN (2M) vs IBIO (375K).
CYCNIBIOCYCN / IBIO
Capitalization9.81M13.9M71%
EBITDA-3.63M-15.11M24%
Gain YTD-0.466-65.6371%
P/E RatioN/A0.65-
Revenue2M375K533%
Total Cash3.23M4.96M65%
Total Debt03.76M-
FUNDAMENTALS RATINGS
CYCN vs IBIO: Fundamental Ratings
CYCN
IBIO
OUTLOOK RATING
1..100
141
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9496
PRICE GROWTH RATING
1..100
6297
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYCN's Valuation (21) in the null industry is in the same range as IBIO (28) in the Biotechnology industry. This means that CYCN’s stock grew similarly to IBIO’s over the last 12 months.

CYCN's Profit vs Risk Rating (100) in the null industry is in the same range as IBIO (100) in the Biotechnology industry. This means that CYCN’s stock grew similarly to IBIO’s over the last 12 months.

CYCN's SMR Rating (94) in the null industry is in the same range as IBIO (96) in the Biotechnology industry. This means that CYCN’s stock grew similarly to IBIO’s over the last 12 months.

CYCN's Price Growth Rating (62) in the null industry is somewhat better than the same rating for IBIO (97) in the Biotechnology industry. This means that CYCN’s stock grew somewhat faster than IBIO’s over the last 12 months.

IBIO's P/E Growth Rating (98) in the Biotechnology industry is in the same range as CYCN (100) in the null industry. This means that IBIO’s stock grew similarly to CYCN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYCNIBIO
RSI
ODDS (%)
Bearish Trend 6 days ago
90%
Bullish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 7 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
Bearish Trend 8 days ago
89%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WSMRX25.470.31
+1.23%
William Blair Small-Mid Cap Growth R6
OIGYX34.72N/A
N/A
Invesco Oppenheimer International Gr Y
JNVSX18.46N/A
N/A
Jensen Quality Mid Cap J
TIHBX13.58N/A
N/A
Transamerica International Stock I
RISRX13.52N/A
N/A
RBC International Small Cap Equity R6

CYCN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCN has been loosely correlated with BLUE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCN jumps, then BLUE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCN
1D Price
Change %
CYCN100%
+8.28%
BLUE - CYCN
36%
Loosely correlated
N/A
HRTX - CYCN
33%
Loosely correlated
+3.63%
FATE - CYCN
29%
Poorly correlated
+4.62%
GDTC - CYCN
29%
Poorly correlated
-7.69%
IBIO - CYCN
25%
Poorly correlated
+2.55%
More

IBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBIO has been loosely correlated with ELVAF. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if IBIO jumps, then ELVAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBIO
1D Price
Change %
IBIO100%
+2.55%
ELVAF - IBIO
39%
Loosely correlated
N/A
REPL - IBIO
38%
Loosely correlated
+0.63%
VOR - IBIO
36%
Loosely correlated
-5.42%
LENZ - IBIO
35%
Loosely correlated
+2.09%
NUVB - IBIO
34%
Loosely correlated
+4.70%
More